Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 4Tumor-Agnostic 2Gynecologic 2CNS 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Angiogenesis Inhibitors × Gynecologic × Clear all
NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
44 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01204749 2016-12-15

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Amgen

Phase 3 Completed
919 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡